BioTuesdays

Category - Markets

Galectin Therapeutics

HCW upgrades Galectin to buy

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin...

Calithera Biosciences

HCW ups Calithera price target to $14

H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on...

Verastem

HCW ups Verastem price target to $6.50

H.C. Wainwright raised its price target for Verastem (NASDAQ:STM) to $6.50 from $5, ahead of a highly anticipated top-line readout from the Phase 3 DUO study of duvelisib for the treatment of relapsed/refractory chronic...

Vital Therapies Logo

Vital Therapies prices $35-million stock offering

Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common shares at a price of $4 each for gross proceeds of approximately $35-million. Vital also granted the underwriters a 30-day...

Checkpoint Therapeutics

Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21. CKPT focuses on combination treatments for solid tumors based...

Oppenheimer Holdings

Oppenheimer expands healthcare investment banking

Oppenheimer & Co., a unit of Oppenheimer Holdings (NYSE:OPY), has hired a new life sciences team, led by Michael Margolis, to join the firm’s healthcare investment banking group. Mr. Margolis will serve as...

Proteon Therapeutics

HCW downgrades Proteon to neutral

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The...

Profound Medical Logo

Echelon starts Profound Medical at buy

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14. Profound has developed MRI-guided...

Aurinia Pharmaceuticals

Aurinia prices $150.5-million stock offering

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has priced a public offering of 22.3 million common shares at a price of $6.75 each for gross proceeds of about $150.5 million. The offering is expected to close on March...

Profound Medical Logo

Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13. “The U.S. is a key target market for the TULSA-PRO system...